Sarepta Therapeutics (SRPT) PT Lowered to $187 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Sarepta Therapeutics (SRPT) Gains 8.5% Off the Open
August 9, 2018 9:40 AM EDTSarepta Therapeutics (NASDAQ: SRPT) gains 8.5% off the open following results, update.
... MoreBaird Reiterates Outperform on Sarepta Therapeutics (SRPT)
August 9, 2018 9:06 AM EDTBaird reiterated an Outperform rating and $202.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) following a quarterly update. Exondys51 sales come in ahead of expectations at $73.5M vs. consensus estimate of $71.0M, a $8.9 sequential increase over 1Q18. Sales continue to track towards the... More
